Literature DB >> 18759506

An automated standardized system for managing adverse events in clinical research networks.

Rachel L Richesson1, Jamie F Malloy, Kathleen Paulus, David Cuthbertson, Jeffrey P Krischer.   

Abstract

Multi-site clinical protocols and clinical research networks require tools to manage and monitor adverse events (AEs). To be successful, these tools must be designed to comply with applicable regulatory requirements, reflect current data standards, international directives and advances in pharmacovigilance, and be convenient and adaptable to multiple needs. We describe an Adverse Event Data Management System (AEDAMS) that is used across multiple study designs in the various clinical research networks and multi-site studies for which we provide data and technological support. Investigators enter AE data using a standardized and structured web-based data collection form. The automated AEDAMS forwards the AE information to individuals in designated roles (investigators, sponsors, Data Safety and Monitoring Boards) and manages subsequent communications in real time, as the entire reporting, review and notification is done by automatically generated emails. The system was designed to adhere to timelines and data requirements in compliance with Good Clinical Practice (International Conference on Harmonisation E6) reporting standards and US federal regulations, and can be configured to support AE management for many types of study designs and adhere to various domestic or international reporting requirements. This tool allows AEs to be collected in a standard way by multiple distributed users, facilitates accurate and timely AE reporting and reviews, and allows the centralized management of AEs. Our design justification and experience with the system are described.

Mesh:

Year:  2008        PMID: 18759506      PMCID: PMC6602073          DOI: 10.2165/00002018-200831100-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  34 in total

1.  Policy and the future of adverse event detection using information technology.

Authors:  David W Bates; R Scott Evans; Harvey Murff; Peter D Stetson; Lisa Pizziferri; George Hripcsak
Journal:  J Am Med Inform Assoc       Date:  2003 Mar-Apr       Impact factor: 4.497

2.  Systematic identification and classification of adverse events in human research.

Authors:  David I Silverman; Lisanne Cirullo; Nicholas A DeMartinis; Kathryn Damato; Margaret DeMeo; Gustavo A Fernandez; Laura Glynn; Upendra Hegde; Elizabeth Laskay; Robin Leger; Khamis Abu-Hasaballah; Joan M Caron
Journal:  Contemp Clin Trials       Date:  2006-03-06       Impact factor: 2.226

3.  Health care quality management by means of an incident report system and an electronic patient record system.

Authors:  Hiroshi Takeda; Yasushi Matsumura; Kazue Nakajima; Shigenori Kuwata; Yang Zhenjun; Ji Shanmai; Zhang Qiyan; Chen Yufen; Hideo Kusuoka; Michitoshi Inoue
Journal:  Int J Med Inform       Date:  2003-03       Impact factor: 4.046

4.  Vaccine Adverse Event Reporting System--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-10-19       Impact factor: 17.586

5.  Automated adverse event detection.

Authors:  Anna M McDaniel
Journal:  Clin Nurse Spec       Date:  2004 Nov-Dec       Impact factor: 1.067

6.  Informatics tools to improve clinical research study implementation.

Authors:  Cynthia A Brandt; Stephanie Argraves; Roy Money; Gowri Ananth; Nina M Trocky; Prakash M Nadkarni
Journal:  Contemp Clin Trials       Date:  2006-01-04       Impact factor: 2.226

7.  Rare disease research gets boost.

Authors:  Tracy Hampton
Journal:  JAMA       Date:  2006-06-28       Impact factor: 56.272

8.  Vaccine-adverse event reporting system: an essential tool for monitoring vaccine safety.

Authors:  Mary S Hayney
Journal:  J Am Pharm Assoc (2003)       Date:  2006 Mar-Apr

9.  Dietary insulin as an immunogen and tolerogen.

Authors:  Minna Tiittanen; Johanna Paronen; Erkki Savilahti; Suvi M Virtanen; Jorma Ilonen; Mikael Knip; Hans K Akerblom; Outi Vaarala
Journal:  Pediatr Allergy Immunol       Date:  2006-11       Impact factor: 6.377

Review 10.  Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.

Authors:  Eleanor S Segal; Cecile Valette; Laurence Oster; Luc Bouley; Catarina Edfjall; Peter Herrmann; Massimo Raineri; Mary Kempff; Saundra Beacham; Cinda van Lierop
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

View more
  1 in total

1.  The Rare Diseases Clinical Research Network's organization and approach to observational research and health outcomes research.

Authors:  Jeffrey P Krischer; Rashmi Gopal-Srivastava; Stephen C Groft; David J Eckstein
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.